Share：
Share this content in WeChat
X
[Chinese][PDF]161
• Clinlcal Guidelines & Expert Consensu •
The interpretation of 2023 ESC guidelines for the management of cardiomyopathies: classification innovation of non-dilated left ventricular cardiomyopathy
KAISAIERJIANG Aisikaier  SA Fen  CHEN Xiuyu  ZHAO Shihua 

Cite this article as: KAISAIERJIANG A, SA F, CHEN X Y, et al. The interpretation of 2023 ESC guidelines for the management of cardiomyopathies: classification innovation of non-dilated left ventricular cardiomyopathy[J]. Chin J Magn Reson Imaging, 2025, 16(4): 1-5. DOI:10.12015/issn.1674-8034.2025.04.001.


[Abstract] The 2023 European Society of Cardiology (ESC) Guidelines for the Management of Cardiomyopathies provide comprehensive guidance on the classification, diagnosis, treatment, and integrated management of cardiomyopathies. Innovatively, the guidelines introduce a new subtype, non-dilated left ventricular cardiomyopathy (NDLVC), emphasizing the critical role of NDLVC phenotypes, genetic testing, and cardiac magnetic resonance (CMR) imaging in the early diagnosis and risk assessment of cardiomyopathies. This approach facilitates more precise identification of cardiomyopathy subtypes and offers novel insights into diagnosis, prognosis evaluation, and risk stratification. It holds promise for delivering earlier and more accurate individualized risk stratification and treatment strategies for NDLVC patients. In this article, the author will focus on the core interpretation of the guidelines regarding the application of CMR and genetic testing in the management of NDLVC, aiming to provide valuable insights for clinicians and radiologists.
[Keywords] non-dilated left ventricular cardiomyopathy；cardiac magnetic resonance；late gadolinium enhancement；genotype；sudden cardiac death

KAISAIERJIANG Aisikaier   SA Fen   CHEN Xiuyu*   ZHAO Shihua  

Department of Magnetic Resonance Imaging, Fuwai Hospital, National Center for Cardiovascular Diseases of China, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China

Corresponding author: CHEN X Y, E-mail: cxy0202@126.com

Conflicts of interest   None.

Received  2024-12-05
Accepted  2025-04-10
DOI: 10.12015/issn.1674-8034.2025.04.001
Cite this article as: KAISAIERJIANG A, SA F, CHEN X Y, et al. The interpretation of 2023 ESC guidelines for the management of cardiomyopathies: classification innovation of non-dilated left ventricular cardiomyopathy[J]. Chin J Magn Reson Imaging, 2025, 16(4): 1-5. DOI:10.12015/issn.1674-8034.2025.04.001.

[1]
ARBELO E, PROTONOTARIOS A, GIMENO J R, et al. 2023 ESC guidelines for the management of cardiomyopathies[J]. Eur Heart J, 2023, 44(37): 3503-3626. DOI: 10.1093/eurheartj/ehad194.
[2]
PINTO Y M, ELLIOTT P M, ARBUSTINI E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases[J]. Eur Heart J, 2016, 37(23): 1850-1858. DOI: 10.1093/eurheartj/ehv727.
[3]
GULATI A, JABBOUR A, ISMAIL T F, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy[J]. JAMA, 2013, 309(9): 896-908. DOI: 10.1001/jama.2013.1363.
[4]
SMITH E D, LAKDAWALA N K, PAPOUTSIDAKIS N, et al. Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy[J]. Circulation, 2020, 141(23): 1872-1884. DOI: 10.1161/CIRCULATIONAHA.119.044934.
[5]
SHUN-SHIN M J, ZHENG S L, COLE G D, et al. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials[J]. Eur Heart J, 2017, 38(22): 1738-1746. DOI: 10.1093/eurheartj/ehx028.
[6]
LORENZINI M, NORRISH G, FIELD E, et al. Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers[J]. J Am Coll Cardiol, 2020, 76(5): 550-559. DOI: 10.1016/j.jacc.2020.06.011.
[7]
CLAES G R F, VAN TIENEN F H J, LINDSEY P, et al. Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers[J]. Eur Heart J, 2016, 37(23): 1815-1822. DOI: 10.1093/eurheartj/ehv522.
[8]
JAMES C A, BHONSALE A, TICHNELL C, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers[J]. J Am Coll Cardiol, 2013, 62(14): 1290-1297. DOI: 10.1016/j.jacc.2013.06.033.
[9]
NEUBAUER S, KOLM P, HO C Y, et al. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry[J]. J Am Coll Cardiol, 2019, 74(19): 2333-2345. DOI: 10.1016/j.jacc.2019.08.1057.
[10]
GIGLI M, MERLO M, GRAW S L, et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy[J]. J Am Coll Cardiol, 2019, 74(11): 1480-1490. DOI: 10.1016/j.jacc.2019.06.072.
[11]
PUGH T J, KELLY M A, GOWRISANKAR S, et al. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing[J]. Genet Med, 2014, 16(8): 601-608. DOI: 10.1038/gim.2013.204.
[12]
ESCOBAR-LOPEZ L, OCHOA J P, MIRELIS J G, et al. Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy[J]. J Am Coll Cardiol, 2021, 78(17): 1682-1699. DOI: 10.1016/j.jacc.2021.08.039.
[13]
HARPER A R, GOEL A, GRACE C, et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity[J]. Nat Genet, 2021, 53(2): 135-142. DOI: 10.1038/s41588-020-00764-0.
[14]
TADROS R, FRANCIS C, XU X, et al. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect[J]. Nat Genet, 2021, 53(2): 128-134. DOI: 10.1038/s41588-020-00762-2.
[15]
PUA C J, THAM N, CHIN C W L, et al. Genetic studies of hypertrophic cardiomyopathy in singaporeans identify variants in TNNI3 and TNNT2 that are common in Chinese patients[J]. Circ Genom Precis Med, 2020, 13(5): 424-434. DOI: 10.1161/CIRCGEN.119.002823.
[16]
PAN J A, KRAMER C M. Cardiac magnetic resonance imaging in heart failure[J/OL]. Cardiovasc Innov Appl, 2024, 9(1) [2024-12-04]. https://doi.org/10.15212/cvia.2024.0037. DOI: 10.15212/cvia.2024.0037.
[17]
MIRELIS J G, ESCOBAR-LOPEZ L, OCHOA J P, et al. Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy[J]. Eur J Heart Fail, 2022, 24(7): 1183-1196. DOI: 10.1002/ejhf.2514.
[18]
CENTURIÓN O A, ALDERETE J F, TORALES J M, et al. Myocardial fibrosis as a pathway of prediction of ventricular arrhythmias and sudden cardiac death in patients with nonischemic dilated cardiomyopathy[J]. Crit Pathw Cardiol, 2019, 18(2): 89-97. DOI: 10.1097/HPC.0000000000000171.
[19]
DE FRUTOS F, OCHOA J P, FERNÁNDEZ A I, et al. Late gadolinium enhancement distribution patterns in non-ischaemic dilated cardiomyopathy: genotype-phenotype correlation[J]. Eur Heart J Cardiovasc Imaging, 2023, 25(1): 75-85. DOI: 10.1093/ehjci/jead184.
[20]
LEO I, DELLEGROTTAGLIE S, SCATTEIA A, et al. CarDiac magnEtic resonance for prophylactic implantable-cardioVerter defibrillAtor ThErapy in non-dilated left ventricular cardiomyopathy: a sub-study from the DERIVATE registry[J/OL]. Eur Heart J Cardiovasc Imaging, 2025: jeaf043 [2024-12-04]. https://pubmed.ncbi.nlm.nih.gov/39899463/. DOI: 10.1093/ehjci/jeaf043.
[21]
KUMAR S, BALDINGER S H, GANDJBAKHCH E, et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers[J]. J Am Coll Cardiol, 2016, 68(21): 2299-2307. DOI: 10.1016/j.jacc.2016.08.058.
[22]
AGARWAL R, PAULO J A, TOEPFER C N, et al. Filamin C cardiomyopathy variants cause protein and lysosome accumulation[J]. Circ Res, 2021, 129(7): 751-766. DOI: 10.1161/CIRCRESAHA.120.317076.
[23]
GASPERETTI A, CARRICK R T, PROTONOTARIOS A, et al. Clinical features and outcomes in carriers of pathogenic desmoplakin variants[J]. Eur Heart J, 2025, 46(4): 362-376. DOI: 10.1093/eurheartj/ehae571.
[24]
GIGLI M, STOLFO D, GRAW S L, et al. Phenotypic expression, natural history, and risk stratification of cardiomyopathy caused by filamin C truncating variants[J]. Circulation, 2021, 144(20): 1600-1611. DOI: 10.1161/CIRCULATIONAHA.121.053521.
[25]
AKHTAR M M, LORENZINI M, PAVLOU M, et al. Association of left ventricular systolic dysfunction among carriers of truncating variants in filamin C with frequent ventricular arrhythmia and end-stage heart failure[J]. JAMA Cardiol, 2021, 6(8): 891-901. DOI: 10.1001/jamacardio.2021.1106.
[26]
EIJGENRAAM T R, BOOGERD C J, STEGE N M, et al. Protein aggregation is an early manifestation of phospholamban p.(Arg14del)-related cardiomyopathy: development of PLN-R14del-related cardiomyopathy[J/OL]. Circ Heart Fail, 2021, 14(11): e008532 [2024-12-04]. https://pubmed.ncbi.nlm.nih.gov/34587756/. DOI: 10.1161/CIRCHEARTFAILURE.121.008532.
[27]
VERSTRAELEN T E, VAN LINT F H M, BOSMAN L P, et al. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction[J]. Eur Heart J, 2021, 42(29): 2842-2850. DOI: 10.1093/eurheartj/ehab294.
[28]
CASTRICHINI M, DE LUCA A, DE ANGELIS G, et al. Magnetic resonance imaging characterization and clinical outcomes of dilated and arrhythmogenic left ventricular cardiomyopathies[J]. J Am Coll Cardiol, 2024, 83(19): 1841-1851. DOI: 10.1016/j.jacc.2024.02.041.
[29]
PIRRUCCELLO J P, BICK A, WANG M X, et al. Analysis of cardiac magnetic resonance imaging in 36, 000 individuals yields genetic insights into dilated cardiomyopathy[J/OL]. Nat Commun, 2020, 11(1): 2254 [2024-12-04]. https://pubmed.ncbi.nlm.nih.gov/34587756/. DOI: 10.1038/s41467-020-15823-7.
[30]
BIDDINGER K J, JURGENS S J, MAAMARI D, et al. Rare and common genetic variation underlying the risk of hypertrophic cardiomyopathy in a national biobank[J]. JAMA Cardiol, 2022, 7(7): 715-722. DOI: 10.1001/jamacardio.2022.1061.
[31]
OMMEN S R, HO C Y, ASIF I M, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy A report of the American heart association/American college of cardiology joint committee on clinical practice guidelines[J]. J Am Coll Cardiol, 2024, 83(23): 2324-2405. DOI: 10.1016/j.jacc.2024.02.014.
[32]
MOHSENI A, ZANDIEH G, PORTER K, et al. Cardiac amyloidosis: a comprehensive review of imaging findings[J/OL]. Acad Radiol, 2025: S1076-6332(25)00064-9 [2024-12-04]. https://pubmed.ncbi.nlm.nih.gov/39893144/. DOI: 10.1016/j.acra.2025.01.022.

PREV Advances in time-dependent diffusion MRI for tumor diagnosis and treatment response evaluation
NEXT Substantia nigra and locus coeruleus neuromelanin magnetic resonance imaging differentiates Parkinson,s disease and multiple system atrophy
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn